Oncology & Cancer

Nivolumab plus ipilimumab tops sunitinib for advanced renal CA

(HealthDay)—For patients with previously untreated clear-cell advanced renal-cell carcinoma, nivolumab plus ipilimumab is associated with better overall survival than sunitinib, according to a study published online March ...

Oncology & Cancer

Atezolizumab + bevacizumab shows benefit in met renal CA

(HealthDay)—For patients with metastatic renal cell carcinoma (mRCC), atezolizumab plus bevacizumab is associated with a progression-free survival benefit versus sunitinib, according to a study presented at the American ...

Oncology & Cancer

Widely used kidney cancer drugs can't stop recurrence

Two widely used targeted therapy drugs approved by the FDA for the treatment of metastatic kidney cancer—sorafenib and sunitinib—are no more effective than a placebo in preventing return of the disease to increase life ...

Oncology & Cancer

Sorafenib, sunitinib may pose cardiovascular risk

(HealthDay)—Older kidney cancer patients treated with sorafenib or sunitinib may face an increased risk of cardiovascular adverse events, according to a study published online Oct. 6 in Cancer.

page 1 from 2